Table 3.

Rank probability in terms of efficacy based on the number of patients that achieved an ASAS20 or ASAS40 response, and the safety based on the number of SAEs

Treatment	SUCRA
A. Efficacy: ASAS20
Tofacitinib 5 mg	0.887
Filgotinib 200 mg	0.788
Upadacitinib 15 mg	0.426
Secukinumab 150 mg	0.399
Placebo	<0.001
B. Efficacy: ASAS40
Tofacitinib 5 mg	0.751
Upadacitinib 15 mg	0.668
Secukinumab 150 mg	0.543
Filgotinib 200 mg	0.535
Placebo	0.003
C. Safety
Tofacitinib 5 mg	0.700
Secukinumab 150 mg	0.553
Filgotinib 200 mg	0.437
Upadacitinib 15 mg	0.431
Placebo	0.379

SUCRA, surface under the cumulative ranking curve.